Pharmacoeconomic comparison of dupilumab and lebrikizumab for atopic dermatitis treatment in Italy: cost-per-responder analysis
{{output}}
Background: A cost per responder model was developed to compare the pharmacoeconomic value of dupilumab and lebrikizumab for the treatment of moderate-to-severe atopic dermatitis (AD) in Italy. ... ...
